Cargando…
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
BACKGROUND: Preclinical studies suggest that histone deacetylase (HDAC) inhibitors may restore tumour sensitivity to retinoids. The objective of this study was to determine the safety, tolerability, and the pharmacokinetic (PK)/pharmacodynamic (PD) profiles of the HDAC inhibitor entinostat in combin...
Autores principales: | Pili, R, Salumbides, B, Zhao, M, Altiok, S, Qian, D, Zwiebel, J, Carducci, M A, Rudek, M A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251867/ https://www.ncbi.nlm.nih.gov/pubmed/22134508 http://dx.doi.org/10.1038/bjc.2011.527 |
Ejemplares similares
-
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
por: Shen, Li, et al.
Publicado: (2012) -
Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
por: Freundt, Johanna K., et al.
Publicado: (2019) -
The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells
por: Nunn, Abigail D. G., et al.
Publicado: (2016) -
Erratum: The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells
por: Nunn, Abigail D. G., et al.
Publicado: (2016) -
Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer
por: Tanioka, Maki, et al.
Publicado: (2018)